Early diagnosis of Alzheimer's disease: Clinical and economic benefits

Journal of the American Geriatrics Society

Volumn 51, Issue 5 SUPPL. II, 2003, Pages

  Leifer, Bennett P ^a  

^a NONE   (United States)

Author keywords

Alzheimer's disease; Alzheimer's disease early diagnosis; Dementia tests; Differential diagnosis of Alzheimer's disease

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; ESTROGEN; GESTAGEN; GINKGO BILOBA EXTRACT; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE; SELEGILINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ACCURACY; AGING; ALZHEIMER DISEASE; AUTOPSY; AWARENESS; BREAST CANCER; CLINICAL TRIAL; COGNITIVE DEFECT; COMMUNITY; DEMENTIA; DEPRESSION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRAWING; DRUG EFFICACY; ECONOMIC ASPECT; ESTROGEN THERAPY; EVALUATION; FEASIBILITY STUDY; GENETIC MARKER; HEALTH CARE COST; HUMAN; INSTITUTIONALIZATION; LABORATORY TEST; MEMORY DISORDER; MENOPAUSAL SYNDROME; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIMARY MEDICAL CARE; PSYCHOSIS; REVIEW; RISK FACTOR; SENESCENCE; SIDE EFFECT; SOCIETY; UNITED STATES;

EID: 0038076419     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.5153.x     Document Type: Review

References (63)

1. Morris JC. Differential diagnosis of Alzheimer's disease. Clin Geriatr Med 1994;10:257-276.
2. Geldmacher DS, Whitehouse PJ. Evaluation of dementia. N Engl J Med 1996;335:330-336.
3. Cummings JL, Cole G. Alzheimer disease. JAMA 2002;287:2335-2338.
4. Chen M. The Alzheimer's plaques, tangles, and memory deficits may have a common origin - Part II. Therapeutic rationale. Front Biosci 1998;8:32-37.
5. Snowdon D. Aging with Grace. What the Nun Study Teaches Us About Leading Longer, Healthier, and More Meaningful Lives. New York: Bantam Doubleday, 2002.
6. Hendrie HC. Epidemiology of dementia and AD. Am J Geriatr Psychiatry 1998;6:S3-S18.
7. Shah Y, Tangalos EG, Peterson RC. Mild cognitive impairment: When is it a precursor to AD? Geriatrics 2000;55:62-68.
8. About Alzheimer's. Available at www.alz.org/AboutAD/overview.htm Accessed January 29, 2003.
9. Evans DA, Scherr PA, Cook NR et al. Estimated prevalence of AD in the United States. Milbank Q 1990;68:267-289.
10. Marin DB, Sewell MC, Schlechter AAD. Accurate and early diagnosis in the primary care setting. Geriatrics 2000;57:36-40.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision. Washington, DC: American Psychiatric Association, 2000.
12. Lockwood KA, Alexopoulos GS, van Gorp WG. Executive dysfunction in geriatric depression. Am J Psychiatry 2002;159:1119-1126.
13. Alexopoulos GS, Meyers B, Young RC et al. The course of geriatric depression with 'reversible dementia': A controlled study. Am J Psychiatry 1993; 150:1693-1699.
14. Honig LS, Mayeux R. Natural history of AD. Aging Clin Exp Res 2001;13: 171-182.
15. Polvikoski T, Sulkava R, Myllykangas L et al. Prevelance of Alzheimer's disease in very old people: A prospective neuropathological study. Neurology 2001;56:1690-1696.
16. Peterson RC, Stevens JC, Ganguli M et al. Practice parameter. Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1142.
17. Petersen RC, Smith GE, Waring SC et al. Mild cognitive impairment. Clinical characteristics and outcome. Arch Neurol 1999;56:303-308.
18. Howieson DB, Dame A, Camicioli R et al. Cognitive markers preceding Alzheimer's dementia in the healthiest oldest old. J Am Geriatr Soc 1997;45: 584-589.
19. Almkvist O, Bason H, Backman L et al. Mild cognitive impairment - an early stage of Alzheimer's disease? J Neurol Transm Suppl 1998;54:21-29.
20. Jack CR Jr, Petersen RC, Xu YC et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-1403.
21. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment. A population-based validation study. Neurology 2001;56:37-42.
22. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 1998;53:127-140.
23. Mortimer JA, Ebbitt B, June SP et al. Predictors of cognitive and functional progression in patients with probable AD. Neurology 1992;42:1689-1696.
24. Agtiero-Torres H, Fratiglioni L, Winblad B. Natural history of AD and other dementias: Review of the literature in light of the findings of the Kungsholmen Project. Int J Geriatr Psychiatry 1998;13:755-766.
25. Small GW, Rabins PV, Barry PP et al. Diagnosis and treatment of AD and related disorders: Consensus statement of the American Association of Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-1371.
26. Rasmusson DX, Brandt J, Steele C et al. Accuracy of clinical diagnosis of Alzheimer's disease and clinical features of patients with non-Alzheimer neuroparhology. Alzheimer Dis Assoc Disord 1996;10:180-188.
27. Larson EB, Edwards JK, O'Meara E et al. Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia. J Gerontol A BiolSci Med Sci 1996;51:M313-M318.
28. Duncan BA, Siegal AP. Early diagnosis and management of AD. J Clin Psychiatry 1998;59(Suppl. 9):15-21.
29. Cummings JL, Frank JC, Cherry D et al. Guidelines for managing AD: Part I, Assessment. Am Fam Physician 2002;65:2263-2272.
30. Bonner LT, Peskind ER. Pharmacologic treatments of dementia. Med Clin North Am 2002;86:657-674.
31. Schweitzer I, Tuckwell V, O'Brien J et al. Is late onset depression a prodrome to dementia? Int J Geriat Psychiatry 2002;17:997-1005.
32. Kral VA, Emery OB. Long-term follow-up of depressive psuedodementia of the aged. Can J Psychiatry 1989;154:497-501.
33. Hargrave R, Reed B, Mungas D. Depressive syndromes and functional disability in dementia. J Geriarr Psychiatry Neurol 2000;13:72-77.
34. Ballard C, Neill D, O'Brien J et al. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord 2000;59:97-106.
35. Jorm AF. Is depression a risk factor for dementia or cognitive decline? A review. Gerontology 2000;46:219-227.
36. Pfeffer RI, Kurosaki TT, Harrah CH et al. Measurements of functional activities in older adults in the community. J Gerontol 1982;37:323-329.
37. Brodaty H, McGilchrist C, Harris L et al. Time until institutionalization and death in patients with dementia: Role of caregiver training and risk factors. Arch Neurol 1993;50:643-650.
38. Knopman D, Donohue JA, Gutterman EM. Patterns of care in the early stages of AD. Impediments to timely diagnosis. J Am Geriatr Soc 2000;48: 300-304.
39. Solomon PR, Hirschoff A, Kelly B et al. A 7 minute neurocognitive screening battery highly sensitive to AD. Arch Neurol 1998;55:349-355.
40. Small GW. Brain imaging surrogate markers for detection and prevention of cognitive aging and AD. In: Fillit HM, O'Connell AW, eds. Drug Discovery and Development for AD. New York: Springer Co, 2000, pp. 42-49.
41. Costa PT, Williams TF, Somerfield M et al. Clinical Practice Guideline Number 19. Early Identification of Alzheimer's Dementia and Related Dementias (AHCPR Publication no. pp 97-703). Rockville, MD: U.S. Department of Health and Human Services, Agency for Healthcare Policy and Research, 1996.
42. Folstein MF, Folstein SE, Fanjiang G. The Mini-Mental State Examination Clinical Guide. Lutz, FL: Psychological Assessment Resources, Inc., 2003.
43. Crom RM, Anthony JC, Bassett SS et al. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993; 269:2386-2391.
44. Powlishta KK, Von Dras DD, Stanford A et al. The clock drawing test is a poor screen for very mild dementia. Neurology 2002;59:898-903.
45. Peterson A, Lantz MS. Is it Alzheimer's? Neuropsychological testing helps to clarify diagnostic puzzle. Geriatrics 2001;56:58-61.
46. Esteban-Santillan C, Pradirsuwan R, Veda H et al. Clock drawing test in very mild Alzheimer's disease. J Am Geriatr Soc 1998;46:1266-1269.
47. Knopman DS, Dekosky ST, Cummings JL et al. Practice parameter. Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the Academy of Neurology. Neurology 2001;56:1143-1153.
48. Small GW, Ercoli LM, Silverman DHS et al. Cerebral metabolic and cognitive decline in persons at genetic risk for AD. Proc Natl Acad Sci 2000;97: 6037-6042.
49. Potkin SG, Anand R, Fleming K et al. Brain metabolic and clinical effects of rivastigmine in AD. Int J Neuropsychopharmacol 2001;4:223-230.
50. Grutzendler J, Morris JC. Cholinesterase inhibitors for AD. Drugs 2001;61: 41-50.
51. Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-blind, placebocontrolled trial of donepezil in patients with AD. Donepezil Study Group. Neurology 1998;50:136-145.
52. Doody RS, Steven JC, Beck C et al. Practice parameter. Management of dementia (an evidence-based review). Neurology 2001;56:1154-1166.
53. Trinh N-H, Hoblyn J, Mohanry S et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: A meta-analysis. JAMA 2003;289:210-216.
54. Englehart MJ, Geerlings MI, Ruitenberg A et al. Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA 2002;287:3223-3229.
55. Sano M, Ernesto C, Thomas RG et al. for the members of the AD Cooperative Study. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for AD. N Engl J Med 1997;336:1216-1222.
56. Kawas C, Resnick S, Morrison A et al. A prospective study of estrogen replacement therapy and the risk of developing AD. The Baltimore Longitudinal Study on Aging. Neurology 1997;48:1517-1521.
57. Writing Group for The Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post menopausal women: Principal results from The Women's Health Initiative randomized controlled trial. JAMA 2002;228:321-333.
58. U.S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions. Recommendations and rationale. Ann Intern Med 2002;137:834-839.
59. VanDongen MCJM, van Rossum E, Kessels AGH et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 2000;48: 1183-1194.
60. National Institute on Aging. Disease-specific estimates of direct and indirect costs of illness and NIH support. 2000, Available at www1.od.nih/gov/osp/ospp/ecostudies/COIreportweb.htm Accessed December 3, 2002.
61. Rice DP, Fillit HM, Max W et al. Prevalence, costs, and treatment of AD and related dementia: A managed care perspective. Am J Manag Care 2001;7: 809-818.
62. Small GW, McDonnell DD, Brooks RL et al. The impact of symptom severity on the cost of AD. J Am Geriatr Soc 2002;50:321-327.
63. Hill JW, Futterman R, Mastey V et al. The effect of donepezil therapy on health costs in a medicare managed care plan. Manag Care Interface 2002; 15:63-70.